Payment overview · 2025
General Payments
$34.56
2 reported records · 1 companies
Healthcare provider profile · identity verified
Brian Keith Carreon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHALLOWATER, TX · NPI 1831162221
Verified facts
What the public records show
CMS Open Payments records show Brian Keith Carreon, M.D. received $34.56 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.56 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 814 | 211 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 100 |
| Metformin Hcl | Metformin Hcl | 327 | 98 |
| Lisinopril | Lisinopril | 321 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 98 |
| Gabapentin | Gabapentin | 268 | 73 |
| Losartan Potassium | Losartan Potassium | 221 | 58 |
| Meloxicam | Meloxicam | 205 | 58 |
| Potassium Chloride | Potassium Chloride | 204 | 72 |
| Montelukast Sodium | Montelukast Sodium | 183 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 181 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 48 |
| Furosemide | Furosemide | 154 | 38 |
| Ozempic | Semaglutide | 151 | 28 |
| Omeprazole | Omeprazole | 149 | 36 |
| Allopurinol | Allopurinol | 142 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 38 |
| Celecoxib | Celecoxib | 138 | 52 |
| Ezetimibe | Ezetimibe | 132 | 36 |
| Jardiance | Empagliflozin | 129 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 36 |
| Eliquis | Apixaban | 113 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 26 |
| Carvedilol | Carvedilol | 106 | 22 |
| Sertraline Hcl | Sertraline Hcl | 106 | 30 |
| Trazodone Hcl | Trazodone Hcl | 106 | 38 |
| Irbesartan | Irbesartan | 93 | 21 |
| Simvastatin | Simvastatin | 93 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 25 |
| Glipizide Er | Glipizide | 79 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Alendronate Sodium | Alendronate Sodium | 62 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 56 | 15 |
| Mounjaro | Tirzepatide | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 19 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Famotidine | Famotidine | 39 | 14 |
| Glipizide | Glipizide | 39 | 12 |
| Finasteride | Finasteride | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 16 |
| Zaleplon | Zaleplon | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Prolia | Denosumab | 23 | 15 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tymlos | Abaloparatide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.56 · 2 records | Amgen Inc. | OTEZLA, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error